The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.
Deborah Mukherji
Honoraria - Janssen Pharmaceutical
Carmel Jo Pezaro
Honoraria - Sanofi
Diletta Bianchini
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
Johann Sebastian De Bono
Consultant or Advisory Role - Johnson & Johnson; Sanofi
Honoraria - Johnson & Johnson; Sanofi